Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies.

IF 2.3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Therapeutics and Clinical Risk Management Pub Date : 2020-12-31 eCollection Date: 2020-01-01 DOI:10.2147/TCRM.S256234

Zhaosheng Jin, Tong J Gan, Sergio D Bergese

引用次数: 20

Abstract

Postoperative nausea and vomiting is one of the most frequent adverse events after surgery and anesthesia. It is distressing for the patient and can lead to other postoperative complications. Management of PONV involves a framework of risk assessment, multimodal risk reduction, and prophylactic measures, as well as prompt rescue treatment. There has been a significant paradigm shift in the approach towards PONV prevention. There have also been several emerging therapeutic options for PONV prophylaxis and treatment. In this review, we will discuss the up-to-date PONV management guidelines and highlight novel therapeutic options which have emerged in the last few years.

Abstract Image

查看原文本刊更多论文

预防和治疗术后恶心和呕吐(PONV):目前的建议和新疗法的综述。

术后恶心和呕吐是手术麻醉后最常见的不良事件之一。这对患者来说是痛苦的，并可能导致其他术后并发症。PONV的管理涉及风险评估框架、多式联运风险降低和预防措施，以及及时的抢救治疗。预防PONV的方法已经发生了重大的范式转变。对于PONV的预防和治疗，也出现了几种新的治疗选择。在这篇综述中，我们将讨论最新的PONV管理指南，并强调在过去几年中出现的新的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

4.80

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.